A detailed history of Woodline Partners LP transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Woodline Partners LP holds 300,825 shares of JANX stock, worth $16.4 Million. This represents 0.13% of its overall portfolio holdings.

Number of Shares
300,825
Previous 29,848 907.86%
Holding current value
$16.4 Million
Previous $1.12 Million 1022.08%
% of portfolio
0.13%
Previous 0.01%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$35.12 - $64.78 $9.52 Million - $17.6 Million
270,977 Added 907.86%
300,825 $12.6 Million
Q1 2024

May 15, 2024

BUY
$7.93 - $49.75 $236,694 - $1.48 Million
29,848 New
29,848 $1.12 Million
Q3 2023

Nov 14, 2023

SELL
$9.56 - $14.0 $493,219 - $722,288
-51,592 Reduced 37.58%
85,708 $863,000
Q1 2023

May 15, 2023

SELL
$11.25 - $22.21 $4.14 Million - $8.17 Million
-368,064 Reduced 72.83%
137,300 $1.66 Million
Q4 2022

Feb 14, 2023

BUY
$11.1 - $18.26 $1.17 Million - $1.92 Million
105,183 Added 26.28%
505,364 $6.66 Million
Q3 2022

Nov 14, 2022

BUY
$10.82 - $16.84 $1.23 Million - $1.92 Million
113,798 Added 39.74%
400,181 $5.42 Million
Q2 2022

Aug 15, 2022

BUY
$9.52 - $15.65 $76,731 - $126,139
8,060 Added 2.9%
286,383 $3.5 Million
Q1 2022

May 16, 2022

BUY
$13.24 - $20.24 $635 - $971
48 Added 0.02%
278,323 $3.99 Million
Q4 2021

Feb 14, 2022

SELL
$15.44 - $27.32 $335,912 - $594,373
-21,756 Reduced 7.25%
278,275 $5.49 Million
Q3 2021

Nov 15, 2021

SELL
$20.7 - $34.69 $708,540 - $1.19 Million
-34,229 Reduced 10.24%
300,031 $6.49 Million
Q2 2021

Aug 16, 2021

BUY
$18.58 - $25.37 $6.21 Million - $8.48 Million
334,260 New
334,260 $8.34 Million

Others Institutions Holding JANX

About Janux Therapeutics, Inc.


  • Ticker JANX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,663,000
  • Market Cap $2.27B
  • Description
  • Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...
More about JANX
Track This Portfolio

Track Woodline Partners LP Portfolio

Follow Woodline Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Woodline Partners LP with notifications on news.